Wave Life Sciences has seen its share price fall 64.0% year to date, yet the valuation checks suggest the stock still screens as expensive rather than a clear bargain. Wave Life Sciences is down 64.0% ...
Wave Life Sciences is rated Hold, reflecting high pipeline potential but significant clinical, regulatory, and commercial risks. WVE-006 regaining global rights from GSK raises both opportunity and ...
Canaccord Genuity initiated RNA-based drug developer Wave Life Sciences (NASDAQ:WVE) with a Buy recommendation and a $19 per share target on Monday, citing multiple stock-moving catalysts for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results